"rationale","uuid:ID","instanceType","versionIdentifier","id"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","882c82ee-3f93-42dd-a3e9-cc611f44c644","StudyVersion","2","StudyVersion_1"
